Abstract:Recent breakthroughs in tumor immunotherapy such as immune checkpoint blockade (ICB) antibodies, have demonstrated the capacity of the immune system to fight cancer in a number of malignancies such as melanoma and lung cancer. The numbers, localization and phenotypes of tumor-infiltrating lymphocytes (TIL) are not only predictive of response to immunotherapy but also key modulators of disease progression. In this review, we focus on TIL profiling in cutaneous melanoma using histopathological approaches and highlight the observed prognostic value of the primary TIL subsets. The quantification of TIL in formalin-fixed tumor samples ranges from visual scoring of lymphocytic infiltrates in H&E to multiplex immunohistochemistry and immunofluorescence followed by enumeration using image analysis software. Nevertheless, TIL enumeration in the current literature primarily relies upon single marker immunohistochemistry analyses of major lymphocyte subsets such as conventional T cells (CD3, CD4, CD8), regulatory T cells (FOXP3) and B cells (CD20). We review key studies in the literature on associations between TIL subsets and patient survival. We also cover recent findings with respect to the existence of ectopic lymphoid aggregates found in the TME which are termed tertiary lymphoid structures (TLS) and are generally a positive prognostic feature. In addition to their prognostic significance, the existence of various TIL sub-populations has also been reported to predict a patient's response to ICB. Thus, the literature on the predictive potential of TIL subsets in melanoma patients receiving ICB has also been discussed. Finally, we describe recently developed state-of-the-art profiling approaches for tumor infiltrating immune cells such as digital pathology scoring algorithms (e.g., Immunoscore) and multiplex proteomics-based immunophenotyping platforms (e.g., imaging mass cytometry). Translating these novel technologies have the potential to revolutionize tumor immunopathology leading to altering our current understanding of cancer immunology and dramatically improving outcomes for patients.

The Prognostic and Biology of Tumour-Infiltrating Lymphocytes in the Immunotherapy of Cancer

The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications

Prognostic Landscape of Tumor-Infiltrating T and B Cells in Human Cancer

The Past, Present and Future of Immunotherapy Against Tumor.

Targeted Anti‐Tumor Immunotherapy Using Tumor Infiltrating Cells

Immune contexture defined by single cell technology for prognosis prediction and immunotherapy guidance in cancer

Significance of intratumoral infiltration of B cells in cancer immunotherapy: From a single cell perspective

Roles and mechanisms of tumour-infiltrating B cells in human cancer: a new force in immunotherapy

Single-Cell Informatics for Tumor Microenvironment and Immunotherapy

Innate Immune Cells in Tumour Microenvironment: A New Frontier in Cancer Immunotherapy

Tumor Immunotherapy: Mechanisms and Clinical Applications

Applications of single-cell analysis in immunotherapy for lung cancer: Current progress, new challenges and expectations

Investigating T Cell Immunity in Cancer: Achievements and Prospects

Tumor-Infiltrating Lymphocytes in Colorectal Cancer: The Fundamental Indication and Application on Immunotherapy

Tumor-Infiltrating Lymphocytes and Their Prognostic Value in Cutaneous Melanoma

Role of the tumor immune microenvironment in tumor immunotherapy

The soldiers needed to be awakened: Tumor-infiltrating immune cells

The emergence of tumor-infiltrating lymphocytes in nasopharyngeal carcinoma: Predictive value and immunotherapy implications

The prognostic landscape of tumor-infiltrating immune cell and immunomodulators in lung cancer.

Progresses in biomarkers for cancer immunotherapy

The prognostic biological markers of immunotherapy for non-small cell lung cancer: current landscape and future perspective